Optimization of an in vitro drug screening assay for anti- Trypanosoma cruzi activity using epimastigotes

Clicks: 15
ID: 327732
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #25 of 33 articles by views in Biology Methods and Protocols

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Chagas disease, caused by Trypanosoma cruzi, poses a significant global health burden. Current treatment relies solely on benznidazole and nifurtimox, both with limited efficacy and significant adverse effects. In vitro phenotype-based screening enables identification of alternative treatments. While epimastigote-based screening is not suitable for primary drug discovery, it provides valuable complementary data for compound evaluation. However, the lack of standardized experimental conditions across studies compromises reproducibility and inter-laboratory comparability. Here we optimized experimental conditions for T. cruzi epimastigote drug susceptibility assays. T. cruzi epimastigotes (strain Y) were cultured under systematically varied conditions to optimize medium composition, serum supplementation, medium replacement frequency, inoculum density, and treatment exposure time. Epimastigote growth peaked on day 8, declining thereafter. Low initial parasite inoculum showed reduced growth and high variability, while high parasite densities formed aggregates. Growth rates were similar across media, but Roswell Park Memorial Institute (RPMI) medium could promote trypomastigote-like forms. Fetal bovine serum (FBS) enhanced growth rates with positive correlation between serum concentration and proliferation. Three-day medium replacement maintained >98% epimastigotes. Benznidazole exhibited an IC₅₀ of 16.61 ± 0.38 µM under optimized conditions. Optimal conditions include: Liver Infusion Tryptose or Brain Heart Infusion medium with 10% FBS, medium replacement every three days, 1 × 106 parasites/mL inoculum, and 72-hour treatment at 28 °C. The assay demonstrated robustness across microplate designs, producing consistent results with both U-bottom and flat-bottom 96-well plates. Under these optimized conditions, benznidazole serves as an effective positive control.
Reference Key
openalex_W7211926631 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jacqueline Perez, María Helena Arias-Marciales, Giovanny Garavito
Are you one of these authors? Claim your profile
Journal Biology Methods and Protocols
Year 2026
DOI
10.1093/biomethods/bpag051
URL
https://doi.org/10.1093/biomethods/bpag051
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.